Loading
companiesCompany
Daehwa Pharmaceutical
Daehwa is a Korean pharmaceutical company whose oral paclitaxel (Liporaxel) was approved in Korea for gastric cancer after a phase 3 trial it led, one of the few oral formulations of a taxane to reach the market.
Also called: Daehwa Pharmaceutical Co., Ltd.Dae Hwa Pharm대화제약
Overview
Daehwa Pharmaceutical Co., Ltd., founded in 1984 and based in Seoul, developed Liporaxel, an oral liquid formulation of paclitaxel that uses a lipid-based system to achieve absorption, and won Korean approval for advanced gastric cancer on a phase 3 trial against intravenous paclitaxel. Further phase 3 trials in breast cancer are registered on ClinicalTrials.gov under Daehwa as lead sponsor.
Headquarters
Seoul, KR
Scorecard
All companies#127of 1244 companies, score 44
- approved products +6
- modalities +2
- regions +6
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 0 targets, 4,398 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1984
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
Similar pages
- CompanyPregLem
- CompanyAtossa Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, HR-positive / HER2-negative breast cancer.
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyCyclacel Pharmaceuticals
cancers
drugs
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane